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ABSTRACT
Introduction: Neovascular age-related macular
degeneration (nAMD) is the leading cause of
vision loss among persons aged 65 years and
older. Anti-vascular endothelial growth factor
(anti-VEGF) treatment is the recommended
standard of care. The current study compares
the effectiveness of ranibizumab in routine
clinical practice in two countries that generally
apply two different treatment regimens,
treat-and-extend (T&E) in Australia or pro re
nata (PRN) in the UK.
Methods: This retrospective, comparative,
non-randomised cohort study is based on
patients’ data from electronic medical record
(EMR) databases in Australia and the UK.
Treatment regimens were defined based on
location, with Australia as a proxy for analysing
T&E and UK as a proxy for analysing PRN. The
study included patients with a diagnosis of
nAMD who started treatment with ranibizumab
between January 2009 and July 2014. A total of
647 eyes of 570 patients in Australia and 3187
eyes of 2755 patients in the UK with complete
12-months follow-up were analysed.
Results: Baseline patient characteristics were
comparable between the two cohorts. After 1
year of treatment, T&E-treated eyes achieved
higher mean (±SE) visual acuity (VA) gains
(5.00 ± 0.54 letters [95% confidence interval
(CI) 3.93–6.06]) than PRN-treated eyes
[3.04 ± 0.24 letters (95% CI 2.57–3.51); differ-
ence in means 2.07 ± 0.69 (95% CI 0.73–3.41),
p\0.001]. Non-inferiority of T&E compared to
PRN was concluded based on the change in
mean visual acuity gains at 12 months. Over the
12-month follow-up, T&E-treated eyes received
a higher mean [±standard deviation (SD)]
number of injections (9.29 ± 2.43) than
PRN-treated eyes (6.04 ± 2.19) (p\0.0001).
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Australian patients had a lower mean (±SD)
number of total clinic visits (10.29 ± 2.90) than
UK patients (11.47 ± 2.93) (p\0.0001).
Conclusion: The higher injection frequency in
the T&E cohort may account for the trend
toward improved vision.
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INTRODUCTION
Age-related macular degeneration (AMD) is the
leading cause of blindness among persons aged
65 years and older [1] and a major cause of
blindness worldwide [2]. The majority of
AMD-associated vision loss is attributable to the
neovascular form of the disease, known as
neovascular AMD (nAMD) [3]. The introduction
of anti-vascular endothelial growth factor
(anti-VEGF) treatment for nAMD has revolu-
tionised its management and visual prognosis.
A simulation modelling study with Australian
patients suggests that intravitreal injections of
ranibizumab (under T&E or PRN) can substan-
tially lower the number of cases of blindness
and visual impairment over 2 years after the
diagnosis of nAMD [4, 5]. Ranibizumab is a
humanised monoclonal antibody fragment that
binds all forms of VEGF-A, and since its intro-
duction in Europe and Australia, it has become
the recommended standard of care in nAMD
management [6–8].
In Australia, ‘treat-and-extend’ (T&E) is the
universally adopted treatment regimen. In a
T&E regimen, patients receive 3 monthly
injections during the loading phase followed by
re-treatment at intervals that may be extended
in a stepwise manner [9, 10], as suggested by
Spaide [11], without the need for additional
monitoring visits. In the UK, guidelines for
ranibizumab treatment in nAMD originally
required a loading phase of 3 monthly injec-
tions, followed by an ‘as needed’ treatment (pro
re nata; PRN) based on disease activity at
monthly assessments [8, 12]. In 2014, the SmPC
for ranibizumab allowed for T&E dosing and
this is now becoming more frequent in UK.
Identifying the optimum treatment regimen
for nAMD remains an ongoing challenge. The
ultimate goal is to reduce the number of
anti-VEGF injections required without sacrificing
visual acuity (VA) gains. A recent systematic
review comparing T&E and PRN anti-VEGF
treatment regimens found that, on average, T&E
results in greater VA gains but also requires more
injections [13]. Similarly, Hatz et al. reported that
ranibizumab when administered using a T&E
regimen in treatment-naı¨ve nAMD patients
resulted inbettervisualoutcomes thanwith aPRN
regimen [14].
The purpose of the current study is to compare
the effectiveness of ranibizumab administered
under two different treatment regimens [T&E
(Australia)orPRN(UK)] in routineclinicalpractice.
METHODS
This was a retrospective, comparative,
non-randomised cohort study. It examined the
effectiveness of two different ranibizumab
treatment posologies in eyes with nAMD. This
study was conducted using pseudo-anony-
mised, highly structured, longitudinal (across
visits and time) data collected within the same
type of electronic medical records (EMR) data-
base (Medisoft Ophthalmology, Medisoft,
Leeds, UK) at each of the four community
Medical Retina Clinics across Australia and five
community Medical Retina clinics across the
UK. Data collected included: demographics, VA
at baseline and at each study visit, injection
frequency and number of monitoring visits.
The study included patients with a diagnosis
of nAMD, who had no anti-VEGF treatment
6 months before the index date and who were
treated exclusively with ranibizumab between
January 2009 and July 2014. The index date is
defined as the first prescription of ranibizumab
captured in the EMR database during the study
period. The end date was chosen in order to
exclude eyes from UK sites where the posology
potentially changed to T&E after the label
change in 2014 [9, 15]. Since then, monthly
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monitoring of nAMD patients receiving ranibi-
zumab was no longer mandatory, allowing for a
more flexible treatment regimen in eyes with
stable disease activity.
After application of the inclusion and exclu-
sion criteria for this study (Fig. 1), EMR data
included 911 eyes of 788 patients in Australia
and 4015 eyes of 3458 patients in the UK. For
647 eyes of 570 patients in Australia and 3187
eyes of 2755 patients in the UK complete
12-month follow-ups were available for analysis.
The primary effectiveness outcome measure
was the mean change in VA from baseline to
month 12. VA values were measured with a
mixture of logMAR (logarithm of the minimum
angle of resolution), ETDRS (early treatment
diabetic retinopathy study) letter scores and
Snellen measures. For the purposes of analysis
all values were converted to ETDRS letter score
values. VA was mainly measured with habitual
correction rather than refracted best-corrected
VA. If more than one measure was recorded for
Fig. 1 Inclusion and exclusion criteria for this study. 1The
diagnosis had to be for the eye(s) where the index injection
had occurred. If both eyes were injected and diagnosed,
both were included. 2Date of ﬁrst RBZ injection; 3in/for
the study eye(s). anti-VEGF anti-vascular endothelial
growth factor, AUS Australia, CF counting ﬁngers, HM
hand motion, nAMD neovascular age-related macular
degeneration, NPL no perception of light, PL perception
of light, PRN pro re nata, RBZ ranibizumab, T&E
treat-and-extend, VA visual acuity
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an eye on the same day, the best VA value was
used for analysis.
Eyes were included if they had been followed
for 12 months; however, because this is a study
conducted in a real-world setting, eyes might
not have been assessed exactly at month 12 (day
360). To address this limitation, ‘month 12’ VA
measurements were defined as any measure-
ment performed between month 9 and month
15 (270–450 days). If more than one measure-
ment was available, the value closest to month
12 was used. If two values had the same dis-
tance, the first one was taken. A similar
approach was used to define VA values for
month 3 (60–120 days) and month 6
(150–210 days).
For the power calculations conducted prior
to study initiation, literature-reported BCVA
changes were considered: Tufail et al. reported a
12-month mean change of BCVA of two letters
[12]. Gillies et al. reported a 12-month mean
change of BCVA of 4.9 letters in an Australian
cohort [16]. Based on this, for the study pre-
sented here, the sample size for the VA outcome
analysis for non-inferiority of AUS vs. UK was
calculated, assuming no difference between the
two groups, a non-inferiority limit of five letters
(equal to one line) and a significance level of
0.05. For simplicity, a common SD of 15.6 was
assumed. As a result a minimum of 167 eyes per
group were needed to achieve at least 90%
power for the VA change at month 12, i.e. with
647 eyes of 570 patients in the AUS group the
sample size was sufficient to assess the main
study objective. Results were presented
descriptively for all outcome parameters. In
terms of comparative analyses, categorical out-
comes were compared via a chi-square test,
while for continuous variables and for differ-
ences in the mean number of visits between the
two groups a two-sided Wilcoxon rank sum test
was used. To test for non-inferiority of T&E vs.
PRN with respect to the difference in VA change
at month 12, a general estimating equation
(GEE) model was used. The GEE model included
the covariates baseline VA and age at baseline
and accounted for possible inter-eye correla-
tion, i.e. the fact that both eyes of a patient
could contribute to the study (bilateral
treatment).
Ethical Approval
This study was designed, implemented and
reported in accordance with the guidelines for
good pharmacoepidemiology practices (GPP) of
the International Society for Pharmacoepidemi-
ology [17], the STROBE (Strengthening the
Reporting of Observational Studies in Epidemi-
ology) guidelines [18] and the ethical principles
laid down in the Declaration of Helsinki. For this
type of study (with all patient identifiers
removed and pseudo-anonymised clinician data)
formal patient informed consent is not required.
RESULTS
Baseline patient characteristics were comparable
between the Australian and the UK cohorts, and
are presented in Table 1. After 1 year of treatment,
the mean [±standard error (SE)] change in VA
from baseline in the T&E-treated Australian
cohort was 5.00 ± 0.54 letters (95% CI 3.93–6.06),
while mean (±SE) change in VA from baseline in
the PRN-treated UK cohort was 3.04 ± 0.24 letters
(95% CI 2.57–3.51) (Table 2). The difference of
mean change between the Australian and the UK
cohorts was 2.07 ± 0.68 letters [(95% CI
0.73–3.41), p\0.001]. Non-inferiority of T&E
compared to PRN was concluded, since the upper
boundary of the two-sided 95% confidence
interval (i.e. 3.41 letters) did not exceed the
non-inferiority margin of ?5 letters. A compar-
ison of the study groups based on the analysis of
covariance adjusting for patient baseline VA yiel-
ded similar results (results not shown).
The proportion of eyes with a VA of \35
letters was similar at baseline and after
12 months under both the T&E regimen
(12.86% vs. 12.21% at baseline; Fig. 2) and the
PRN regimen (11.89% vs. 11.52% at baseline).
Improved vision under both regimens was
concluded for two reasons: (1) The proportion
of eyes with VA of 35–55 letters at month 12
had decreased under both regimens (T&E
20.48% vs. 34.47% at baseline; PRN 27.70% vs.
37.68% at baseline). (2) The proportion of eyes
achieving[70 letters at month 12 had increased
compared to baseline (T&E 35.24% vs. 21.48%
at baseline; PRN 29.63% vs. 17.29% at baseline).
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Within the loading phase, i.e. the first
3 months of monthly initial loading injections,
the mean VA increased quickly under both T&E
and PRN (Fig. 3). Subsequently, a positive trend
remained for T&E at month 6, whereas the
mean VA for PRN-treated eyes gradually
declined from month 3 to 12. At month 12, eyes
under a T&E regimen maintained higher mean
VA gains compared to PRN.
There was no difference in the mean number
of injections received during the loading phase,
with eyes treated under the T&E regimen
receiving a mean (±SD) of 2.25 ± 0.67 injec-
tions and eyes treated under the PRN regimen
receiving a mean (±SD) of 2.30 ± 0.60 injec-
tions (p\0.0827; Supplementary Figure S1).
However, over the 12-month follow-up, eyes
treated under T&E received a higher mean
Table 1 Patient demographics and baseline characteristics among patients receiving ranibizumab for nAMD treatment in
the health care settings of Australia and UK
AUS cohort UK cohort p value
Patients N = 570 N = 2755
Eyes N = 647 N = 3187
Mean [SD] age in years 78.49 [6.76] 77.96 [8.14] 0.6573
Proportion of patients per age group at index date in % 0.0027
\65 years 3.40 6.46
65–69 years 9.58 6.78
70–74 years 12.67 12.52
75–79 years 19.17 21.65
80–84 years 36.01 32.44
C85 years 19.17 20.14
Gender (patient) in % 0.0312
Female 57.82 63.67
Male 42.18 36.33
VA study eye (eye) 0.1979
N 647 3187
Mean [SD], letters 54.89 [18.82] 55.05 [15.59]
VA fellow eye (eye) \0.0001
N 273 2883
Mean [SD], letters 65.19 [18.56] 59.65 [23.86]
VA functional groups (eye)
[70 letters 21.48 17.29
56–70 letters 31.84 33.51
35–55 letters 34.47 37.68
\35 letters 12.21 11.52
AUS Australia, N number of eyes, SD standard deviation, VA visual acuity
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(±SD) number of injections (9.29 ± 2.43) vs.
PRN-treated eyes (6.04 ± 2.19, p\0.0001).
The mean (±SD) total number of clinic visits
was lower under a T&E regimen than under a
PRN regimen (T&E 10.29 ± 2.90; PRN
11.47 ± 2.93, p\0.0001; Fig. 4). Of note, in
both Australia and the UK, some clinics run a
two-stop service, i.e. the clinical assessment and
treatment administration occur on different
days. The primary analysis counted all visits
separately. In an additional analysis, multiple
visits occurring within 2 weeks of an injection
were considered as one single injection visit.
After adjusting for these two-stop visits the
inter-country difference regarding the total
number of visits remained statistically signifi-
cant (p\0.0001; Supplementary Figures S2, S3).
The UK cohort also had a larger number of
non-injection visits (p\0.0001; Fig. 4).
DISCUSSION
To our knowledge, this study is the largest,
real-world, comparative analysis of T&E and
PRN treatment regimens with ranibizumab in
Table 2 Mean change from baseline in VA—12-month
follow-up cohort
AUS cohort UK cohort
VA at baseline
LS mean estimate 55.49 55.11
SE 0.65 0.29
95% CI 54.22 65.77 54.55 55.67
VA at month 12
LS mean estimate 60.41 58.17
SE 0.73 0.32
95% CI 58.98 61.84 57.54 58.80
Mean changes at month 12
LS mean estimate 5.00 3.04
SE 0.54 0.24
95% CI 3.93 6.06 2.57 3.51
GEEa
Patients N = 553 N = 2727
Difference of mean change AUS vs. UK at month 12
LS mean estimate 2.07
SE 0.68
95% CI 0.73 3.41
Non-inferiority of T&E vs. UK was concluded since the
upper boundary of the conﬁdence interval (i.e. 3.41) is
smaller than the non-inferiority margin of ?5 letters
AUS Australia, CI conﬁdence interval, GEE general esti-
mating equations, LS least square, N number of eyes, SE
standard error, VA visual acuity
a The GEE model included the covariates baseline VA and
age at baseline. A comparison of the study groups based on
the analysis of covariance adjusting for patient baseline VA
yielded similar results (results not shown)
Fig. 2 Proportion of eyes (in %) per pre-deﬁned VA
category. a At baseline; b at 12 months. For each VA
category the proportion of eyes was compared between
T&E and PRN at 12 months, using a logistic regression
model. After adjustment of the odds ratio for baseline VA,
the decrease in the proportion of eyes achieving 35–55
letters in Australia (i.e. T&E) was signiﬁcantly larger when
compared to the UK (i.e. PRN) (p\0.001). For the
remainder categories this test did not reach statistical
signiﬁcance. AUS Australia, PRN pro re nata, T&E
treat-and-extend, VA visual acuity
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nAMD. The T&E regimen resulted in a better
visual outcome at 12 months compared to PRN.
As this difference was less than ?5 letters/one
line on the ETDRS chart, the T&E regimen was
concluded to be non-inferior to PRN.
Unsurprisingly, the T&E regimen resulted in
substantially fewer monitoring visits; however,
patients treated under this regimen did receive
more injections.
Several studies have reported that T&E is
superior to PRN in terms of visual outcomes
achieved [13, 14, 19]. Furthermore, in the ret-
rospective consecutive comparative case series
study by Hatz and Pru¨nte [14], the T&E regimen
resulted in a statistically significant greater
mean change in VA from baseline with fewer
clinic visits compared to a PRN regimen. In
another case series of treatment-naı¨ve patients,
Hatz and Pru¨nte [20] found a positive mean VA
trend after switching regimens from PRN to
T&E. Patients with active disease regained pre-
vious losses in VA experienced during the PRN
maintenance phase, and a statistically signifi-
cant mean VA increase was observed at 6 and
12 months. While the primary outcome of this
study demonstrated non-inferiority of T&E
compared to PRN, it is noteworthy that the
mean change in VA from baseline under the
T&E regimen compared to a PRN regimen was
also statistically significant. Patients treated
under T&E gained two additional letters com-
pared to those treated under a PRN regimen.
Despite our conclusion of non-inferiority
between posologies in terms of vision, the sig-
nificant variation in injection frequency and
clinic visits between Australia and the UK war-
rants discussion. Unsurprisingly, we report that
during the 12-month follow-up, eyes treated
under a T&E regimen received a higher mean
number of injections than those under a PRN
regimen (9.29 injections for T&E vs. 6.04
injections for PRN). The total number of visits
also differed between the two posologies: in
comparison to T&E, the PRN-treated patients
had a higher mean number of total visits (±SD)
during the first year of treatment (T&E
10.29 ± 2.90 vs. PRN 11.47 ± 2.93, p\0.0001),
particularly monitoring visits.
The higher injection frequency in the T&E
cohort may account for both the trend toward
improved vision and the reduction in the
number of patients with very poor vision, in
this group. Such a finding will be of particular
interest to health care professionals/clinics in
selecting a treatment posology for their patients
Fig. 3 Mean VA change from baseline by time and
country—12-month follow-up cohort. Non-inferiority of
T&E compared to PRN was concluded [T&E vs. PRN:
2.07 ± 0.68 (95% CI 0.73–3.41), GEE model] based on
mean change in VA (±SE) from baseline to month 12. A
comparison of the study groups based on the analysis of
covariance adjusting for patient baseline VA yielded similar
results (results not shown). AUS Australia, error bars 95%
CI values, PRN pro re nata, T&E treat-and-extend, VA
visual acuity
Fig. 4 Mean number of injection visits vs. non-injection
visits. During their ﬁrst year of treatment, T&E-treated
eyes/patients had a signiﬁcantly lower mean (±SD)
number of non-injections visits (i.e. monitoring visits for
visual acuity, optical coherence tomography or intraocular
pressure; p\0.0001) and received a signiﬁcantly higher
mean (±SD) number of injections than PRN-treated eyes
(p\0.0001). Differences in the mean number of visits
between Australia vs. the UK were compared using a
two-sided Wilcoxon rank sum test based on normal
approximation. AUS Australia, N number of eyes, PRN
pro re nata, T&E treat-and-extend
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and to those considering switching patients
from one posology to another. Aside from visual
outcomes, the treatment burden associated
with intravitreal therapy in nAMD is an ongo-
ing challenge for care givers, especially since it
is suggested to contribute to poor long-term
outcomes [21]. Any posology that can reduce
the number of treatment and monitoring visits
while maintaining vision (vs. comparator
treatment posology) may help addressing this
current unmet need in nAMD management.
The current findings also provide useful
insights into effects of treatment posology on
visual outcomes in clinical trials vs. real-world
clinical practice. A recent large study using EMR
data showed that in the UK (where the PRN
regimen was generally used before the ranibi-
zumab label changed), VA gains in a large,
real-world population did not match those
expected based on results seen in RCTs [12].
Among the reasons suggested for this was
under-treatment and failure to achieve monthly
follow-up. Our study suggests that moderate
real-world outcomes cannot be entirely attrib-
uted to the posology used. The non-inferiority
of T&E to PRN in the current study may indicate
that the discrepancy between outcomes in
clinical trials vs. clinical practice are more likely
to be influenced by real-world population dif-
ferences compared to the highly controlled
populations included in RCTs. A recent study
comparing outcomes from a phase III popula-
tion (MARINA) with those of an observational
cohort [Fight Retinal Blindness! (FRB-ALL)] and
a matched observational cohort (FRB-MARINA)
supports this view [16]. Despite comparable
outcomes between all cohorts, the mean
improvement was less for the FRB cohorts than
for the MARINA clinical trial cohort. Interest-
ingly, the mean VA gains in the EMR database
study presented here are quite similar to those
of the total FRB cohort (FRB-ALL).
Some limitations need to be considered for this
study. First, treatment regimens were defined
solely based on location, i.e. the study was anal-
ysed under the assumption that all patients in
Australia and the UK were managed under T&E
and PRN regimens, respectively. Consequently,
some patients may have been assessed under the
wrong treatment regimen. However, based on the
number of injections and visits observed in this
study in the two countries, the assumption con-
cerning the predominant treatment regimens in
each of the two countries was generally con-
firmed. Second, the Australian cohort was only
one-fourth of the size of the UK cohort. Never-
theless the number of sites (four in Australia, five
in UK) was similar and there was no mono-centre
bias. Overall, the number of patients was large
enough to measure all outcomes of interest in
both cohorts. Third, only sites using the Medisoft
EMR system participated, which could result in a
selection bias. There is evidence in the literature
for modest differences in VA outcomes between
centres in the UK [22]. The authors associated this
inter-centre variation with differences in patient
age, starting VA, number of injections and visits.
However, in the study presented here, these fac-
tors were comparable. Using the same EMR sys-
tem allowed consistent data collection, which is
advantageous for study conduct and data analy-
sis. For VA measurements different vision tests
were used; in both cohorts VA was mostly mea-
sured in letter score (80% vs. 91%). Fourth, as
patients with insufficient follow-up time were
excluded, a selection for patients with better
outcomes could be expected, although this would
affect both cohorts. A final limitation may be that
the study did not take into account differences in
genetic background as potentially influencing
factors.
A key strength of this study relates to the use
of EMR data, i.e. a collection of highly struc-
tured data at each visit. Independent of the
regimen applied, EMR are very representative of
real-life clinical care. Outcome data are col-
lected as well, which are not available in some
other data sources. The data shown here gen-
erally confirm the predominant treatment reg-
imens in the two countries during the study
period. With both treatment regimens VA
improvements were observed, supporting
results from clinical trials [13, 19].
CONCLUSION
In conclusion, both regimens of ranibizumab,
T&E and PRN, led to VA improvements and
represent effective treatment strategies for
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nAMD. No difference in the number of injec-
tions received during the loading phase was
observed between the two groups. However, the
T&E regimen resulted in a better outcome as
evidenced in the difference of the mean chan-
ges in visual acuity from baseline to month 12
(primary outcome measure), which may be
accounted for by the higher mean number of
injections administered under this regimen.
These results may be useful for health care
professionals in determining a suitable treat-
ment regimen for patients that considers vision
improvement and the burden associated with
intravitreal therapy.
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